1. Home
  2. CEP vs VERU Comparison

CEP vs VERU Comparison

Compare CEP & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CEP
  • VERU
  • Stock Information
  • Founded
  • CEP 2020
  • VERU 1971
  • Country
  • CEP United States
  • VERU United States
  • Employees
  • CEP N/A
  • VERU N/A
  • Industry
  • CEP
  • VERU Biotechnology: Pharmaceutical Preparations
  • Sector
  • CEP
  • VERU Health Care
  • Exchange
  • CEP NYSE
  • VERU Nasdaq
  • Market Cap
  • CEP 128.4M
  • VERU 113.1M
  • IPO Year
  • CEP 2024
  • VERU 1990
  • Fundamental
  • Price
  • CEP $10.05
  • VERU $0.86
  • Analyst Decision
  • CEP
  • VERU Strong Buy
  • Analyst Count
  • CEP 0
  • VERU 4
  • Target Price
  • CEP N/A
  • VERU $4.00
  • AVG Volume (30 Days)
  • CEP 10.4K
  • VERU 578.7K
  • Earning Date
  • CEP 01-01-0001
  • VERU 12-06-2024
  • Dividend Yield
  • CEP N/A
  • VERU N/A
  • EPS Growth
  • CEP N/A
  • VERU N/A
  • EPS
  • CEP N/A
  • VERU N/A
  • Revenue
  • CEP N/A
  • VERU $14,091,909.00
  • Revenue This Year
  • CEP N/A
  • VERU N/A
  • Revenue Next Year
  • CEP N/A
  • VERU N/A
  • P/E Ratio
  • CEP N/A
  • VERU N/A
  • Revenue Growth
  • CEP N/A
  • VERU N/A
  • 52 Week Low
  • CEP $9.99
  • VERU $0.36
  • 52 Week High
  • CEP $10.07
  • VERU $1.92
  • Technical
  • Relative Strength Index (RSI)
  • CEP N/A
  • VERU 53.67
  • Support Level
  • CEP N/A
  • VERU $0.80
  • Resistance Level
  • CEP N/A
  • VERU $1.00
  • Average True Range (ATR)
  • CEP 0.00
  • VERU 0.06
  • MACD
  • CEP 0.00
  • VERU 0.01
  • Stochastic Oscillator
  • CEP 0.00
  • VERU 49.81

About CEP CANTOR EQUITY PARTNERS INC

Cantor Equity Partners Inc is a blank check company.

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Share on Social Networks: